lomustine has been researched along with ly-2157299 in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Azaro, A; Baselga, J; Carducci, M; Cleverly, AL; Corretti, M; Dolan, M; Fernández, MS; Gueorguieva, I; Kovacs, RJ; Lahn, MM; Maldonado, G; Pillay, NS; Romero, FL; Sepulveda-Sánchez, JM | 1 |
| Azaro, A; Baselga, J; Blakeley, J; Braña, I; Calvo, E; Carducci, M; Cleverly, A; Desaiah, D; Estrem, ST; Gueorguieva, I; Holdhoff, M; Lahn, MM; Paz-Ares, L; Pillay, NS; Rodón, J; Seoane, J; Sepulveda-Sánchez, JM; Sicart, E | 1 |
| Brandes, AA; Capper, D; Carpentier, AF; Cher, L; Chinot, O; Cleverly, A; Desaiah, D; Guba, SC; Gueorguieva, I; Kesari, S; Lahn, MM; Miles, C; Rodon, J; Sepulveda-Sanchez, JM; Smith, C; Specenier, P; Steinbach, JP; Wheeler, HR; Wick, W | 1 |
| Brandes, AA; Capper, D; Carpentier, AF; Cher, L; Chinot, O; Cleverly, A; Desaiah, D; Estrem, ST; Guba, SC; Gueorguieva, I; Kesari, S; Lahn, MM; Miles, C; Rodon, J; Sepulveda-Sanchez, JM; Smith, C; Specenier, P; Steinbach, JP; von Deimling, A; Wheeler, HR; Wick, W | 1 |
4 trial(s) available for lomustine and ly-2157299
| Article | Year |
|---|---|
Cardiac Safety of TGF-β Receptor I Kinase Inhibitor LY2157299 Monohydrate in Cancer Patients in a First-in-Human Dose Study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Blood Pressure; Echocardiography, Doppler; Electrocardiography; Female; Heart Diseases; Humans; Lomustine; Male; Middle Aged; Neoplasms; Prospective Studies; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Pyrazoles; Quinolines; Receptor, Transforming Growth Factor-beta Type I; Receptors, Transforming Growth Factor beta; Risk Assessment; Risk Factors; Signal Transduction; Spain; Time Factors; Treatment Outcome; Young Adult | 2015 |
Pharmacokinetic, pharmacodynamic and biomarker evaluation of transforming growth factor-β receptor I kinase inhibitor, galunisertib, in phase 1 study in patients with advanced cancer.
Topics: ADAM Proteins; Adult; Aged; Anticonvulsants; Area Under Curve; Blood Cell Count; Chemokine CCL22; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Enzyme-Linked Immunosorbent Assay; Female; Humans; Leukocytes, Mononuclear; Lomustine; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Protein Serine-Threonine Kinases; Proton Pump Inhibitors; Pyrazoles; Quinolines; Receptor, Transforming Growth Factor-beta Type I; Receptors, Transforming Growth Factor beta; Smad2 Protein; Tumor Suppressor Proteins | 2015 |
A Phase II randomized study of galunisertib monotherapy or galunisertib plus lomustine compared with lomustine monotherapy in patients with recurrent glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Disease-Free Survival; Drug Therapy, Combination; Female; Glioblastoma; Humans; Kaplan-Meier Estimate; Lomustine; Male; Middle Aged; Pyrazoles; Quinolines; Treatment Outcome | 2016 |
Biomarker and Histopathology Evaluation of Patients with Recurrent Glioblastoma Treated with Galunisertib, Lomustine, or the Combination of Galunisertib and Lomustine.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; CD4-CD8 Ratio; Cytokines; Female; Forkhead Transcription Factors; Glioblastoma; Humans; Isocitrate Dehydrogenase; Lomustine; Male; Neoplasm Recurrence, Local; Pyrazoles; Quinolines; Smad2 Protein; Survival Analysis | 2017 |